Erratum: Bleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs (Cancer Gene Therapy (2010) 17 (571-578) DOI: 10.1038/cgt.2010.13);Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring spontaneous neoplasms in dogs

Cancer Gene Therapy

Volumn 17, Issue 8, 2010, Pages 571-578

  Reed, S D ^a   Fulmer, A ^a   Buckholz, J ^a   Zhang, B ^a   Cutrera, J ^a   Shiomitsu, K ^a   Li, S ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

BLM; Canine; Electroporation; Interleukin 12; Neoplasia

Indexed keywords

BLEOMYCIN; FELINE LEUKEMIA VIRUS VECTOR; INTERLEUKIN 12; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; DNA;

ACANTHOMATOUS AMELOBLASTOMA; AMELOBLASTOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; CYTOTOXICITY; DOG; DRUG EFFICACY; ELECTROCHEMOGENETHERAPY; ELECTROCHEMOTHERAPY; EUTHANASIA; FELINE LEUKEMIA VIRUS; FEMALE; FIBROSARCOMA; HISTIOCYTIC SARCOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MANDIBLE; MELANOMA; MOUTH CANCER; MOUTH CARCINOMA; NEOPLASM; NONHUMAN; ORAL SQUAMOUS CELL CARCINOMA; OSTEOLYSIS; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; SOFT PALATE FIBROSARCOMA; SPLEEN CANCER; SPLEEN METASTASIS; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; VIRAL GENE THERAPY; WORLD HEALTH ORGANIZATION; ANIMAL; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; CAT; DOG DISEASES; GENE THERAPY; GENETICS; INTRALESIONAL DRUG ADMINISTRATION; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; RETRACTED ARTICLE; TUMOR CELL LINE; VETERINARY;

CANIS FAMILIARIS; FELIDAE; MUS;

ANIMALS; BLEOMYCIN; CARCINOMA, SQUAMOUS CELL; CATS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA; DOG DISEASES; DOGS; ELECTROCHEMOTHERAPY; GENETIC THERAPY; INJECTIONS, INTRALESIONAL; INTERLEUKIN-12; MICE; NEOPLASMS;

EID: 77954819418     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.59     Document Type: Erratum

References (25)

1. Mir LM. Application of electroporation gene therapy: past, current, and future. Methods Mol Biol 2008; 423: 3-17.
2. Miyazaki M, Obata Y, Abe K, Furusu A, Koji T, Tabata Y et al. Gene transfer using nonviral delivery systems. Perit Dial Int 2006; 26: 633-640.
3. Teissie J, Golzio M, Rols MP. Mechanisms of cell membrane electropermeabilization: a minireview of our present (lack of?) knowledge. Biochim Biophys Acta 2005; 1724: 270-280.
4. Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003; 177: 437-447.
5. Reed SD, Li S. Electroporation advances in large animals. Curr Gene Ther 2009; 9: 316-326.
6. Sammeta SM, Vaka SR, Narasimha Murthy S. Transdermal drug delivery enhanced by low voltage electropulsation (LVE). Pharm Dev Technol 2009; 14: 159-164.
7. Barbul A, Antov Y, Rosenberg Y, Korenstein R. Enhanced delivery of macromolecules into cells by electroendocytosis. Methods Mol Biol 2009; 480: 141-150.
8. Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009; 16: 191-199.
9. Cemazar M, Tamzali Y, Sersa G, Tozon N, Mir LM, Miklavcic D et al. Electrochemotherapy in veterinary oncology. J Vet Intern Med 2008; 22: 826-831.
10. Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res 2006; 16: 182-188.
11. Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P. Cancer immunoprevention. Future Oncol 2005; 1: 57-66.
12. Mortara L, Giuliani L, De Lerma Barbaro A, Accolla RS, Noonan DM. Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer. Surg Oncol 2007; 16(Suppl 1): S33-S36.
13. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 2007; 7: 1705-1721.
14. Mazzolini G, Prieto J, Melero I. Gene therapy of cancer with interleukin-12. Curr Pharm Des 2003; 9: 1981-1991.
15. Persano L, Crescenzi M, Indraccolo S. Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 2007; 28: 87-114.
16. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-5903.
17. Torrero MN, Henk WG, Li S. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electro-chemogenetherapy. Clin Cancer Res 2006; 12: 257-263.
18. Takimoto CH CE. Principles of oncologic pharmacotherapy. In: Pazdur R WL, Camphausen KA, Hoskins WJ, (edn). Cancer Management: A Multidisciplinary Approach. 11 ed. 2008.
19. Spugnini EP, Vincenzi B, Citro G, Tonini G, Dotsinsky I, Mudrov N et al. Electrochemotherapy for the treatment of squamous cell carcinoma in cats: a preliminary report. Vet J 2009; 179: 117-120.
20. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29: 371-387.
21. Kishida T, Asada H, Itokawa Y, Yasutomi K, Shin-Ya M, Gojo S et al. Electrochemo-gene therapy of cancer: intra-tumoral delivery of interleukin-12 gene and bleomycin synergis-tically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. Mol Ther 2003; 8: 738-745.
22. Buttner M, Belke-Louis G, Rziha HJ, McInnes C, Kaaden OR. Detection, cDNA cloning and sequencing of canine interleukin 12. Cytokine 1998; 10: 241-248.
23. Ehrhart N. Soft-tissue sarcomas in dogs: a review. J Am Anim Hosp Assoc 2005; 41: 241-246.
24. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L et al. The dog as a cancer model. Nat Biotechnol 2006; 24: 1065-1066.
25. Cutrera J, Torrero M, Shiomitsu K, Mauldin N, Li S. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. Met Mol Biol 2008; 423: 319-325.